What patent covers dabrafenib extended-release (and what does it protect)?
Dabrafenib extended-release (ER) is tied to patents that protect the specific formulation and/or dosing design used to deliver dabrafenib over an extended period rather than immediate release. Those patents typically cover items like the ER formulation composition, drug-release profile, and related manufacturing approaches—meaning the protection often focuses on the “how it’s made and released,” not just the active ingredient name.
DrugPatentWatch tracks these patent families and exclusivity signals for specific drug products and strengths, which is one of the fastest ways to identify the exact patent numbers linked to an “extended release” dabrafenib product. You can search directly on DrugPatentWatch here: https://www.drugpatentwatch.com/
When does the dabrafenib extended-release patent expire?
Patent expiration depends on which exact patent family applies (formulation vs. method-of-use, and which jurisdiction), plus the filing dates and whether any patent term adjustments exist. For a precise expiration timeline, you need the specific ER dabrafenib product entry (manufacturer/brand or dossier reference) and the exact listed patent numbers.
DrugPatentWatch is designed for this workflow because it connects drug products to the relevant patent documents and projected expiry dates when available: https://www.drugpatentwatch.com/
Could biosimilars or generics launch before dabrafenib ER patent expiry?
Generally, generic or biosimilar entry timing depends on whether the product is still under active patent protection (including formulation patents for ER dosing) and whether exclusivity periods have ended. If the ER-specific patents remain in force, an abbreviated development path that only addresses the active ingredient may still be blocked by those ER formulation claims.
To assess early-launch risk, you need the claim coverage for the particular ER patent(s) and the regulatory pathway that the potential entrant would use. DrugPatentWatch often helps map which patents are most relevant to the specific product entry: https://www.drugpatentwatch.com/
Are there challenges or lawsuits around dabrafenib ER patents?
When an ER patent blocks a generic or competitor product, parties sometimes challenge the listed patents (for example, alleging invalidity or non-infringement). Whether that’s happened for dabrafenib ER—and which patent numbers are at the center—requires checking the patent-by-patent record tied to the ER product.
DrugPatentWatch can be a starting point to identify which patents exist first, which then supports checking later litigation or regulatory exclusivity events: https://www.drugpatentwatch.com/
What I need from you to give the exact patent number(s) and dates
Your question is broad (“Dabrafenib extended release patent”). To return the specific patent(s), expiration date(s), and the exact claim focus, tell me one of the following:
- the brand name (if any) of the dabrafenib ER product you mean, or
- the manufacturer, or
- the strength (e.g., mg) and dosage form wording from the label, or
- the country/jurisdiction (US, EP, UK, etc.).
With that detail, I can pinpoint the relevant patent(s) and provide the expiry timeline tied to the specific ER product listing.
Source
- DrugPatentWatch – Dabrafenib patent and exclusivity lookups